A Systematic Review and Meta-Analysis of Clinical Outcomes of Intravitreal Anti-VEGF Agent Treatment Immediately after Cataract Surgery for Patients with Diabetic Retinopathy

Table 4

Meta-analytic findings about postoperative best-corrected visual acuity compared to the baseline.

	No. of studies	Mean difference (95% CI)		I^2 (%)	for heterogeneity
BCVA after 1 week
IVR for NPDR without DME (LogMAR)	1 [16]	−0.06 (−0.18, 0.06)	0.32	Not applicable
IVR for NPDR without DME (Snellen)	2 [17, 19]	0.04 (−0.04, 0.12)	0.35	50	0.16
IVB for NPDR with DME (LogMAR)	1 [21]	−0.13 (−0.51, 0.25)	0.50	Not applicable
IVR for NPDR with DME (Snellen)	1 [18]	0.16 (0.02, 0.30)	0.02	Not applicable
Total: (LogMAR)	2 [16, 21]	−0.07 (−0.18, 0.05)	0.25	0	0.73
Total: (Snellen)	3 [17–19]	0.06 (−0.01, 0.14)	0.11	51	0.13
BCVA after 1 month
IVB for NPDR without DME (LogMAR)	1 [12]	−0.24 (−0.34, −0.14)	0.00001	Not applicable
IVR for NPDR without DME (LogMAR)	1 [16]	−0.07 (−0.17, 0.03)	0.15	Not applicable
IVR for NPDR without DME (Snellen)	1 [19]	0.15 (0.09, 0.21)	0.00001	Not applicable
IVB for NPDR with DME (LogMAR)	2 [13, 21]	−0.20 (−0.37, −0.03)	0.02	0	0.75
IVR for NPDR with DME (Snellen)	1 [18]	0.19 (0.01, 0.37)	0.04	Not applicable
Total: (LogMAR)	6 [11–13, 15, 16, 21]	−0.14 (−0.19, −0.09)	0.0001	50	0.07
Total: (Snellen)	2 [18, 19]	0.15 (0.10, 0.21)	0.00001	0	0.68
BCVA after 3 months
IVB for NPDR without DME (LogMAR)	1 [12]	−0.04 (−0.14, 0.06)	0.41	Not applicable
IVR for NPDR without DME (LogMAR)	1 [16]	−0.03 (−0.12, 0.06)	0.50	Not applicable
IVR for NPDR without DME (Snellen)	1 [19]	0.20 (0.15, 0.25)	0.00001	Not applicable
IVB for NPDR with DME (LogMAR)	2 [13, 21]	−0.13 (−0.24, −0.02)	0.02	0	0.91
IVB for NPDR with DME (Snellen)	1 [14]	0.19 (0.02, 0.36)	0.03	Not applicable
IVR for NPDR with DME (Snellen)	1 [18]	0.23 (0.05, 0.41)	0.01	Not applicable
Total: (LogMAR)	6 [11–13, 15, 16, 21]	−0.06 (−0.11, −0.01)	0.02	0	0.58
Total: (Snellen)	3 [14, 18, 19]	0.20 (0.16, 0.25)	0.00001	0	0.94
BCVA after 6 months
IVB for NPDR without DME (LogMAR)	1 [12]	0.00 (−0.10, 0.10)	1.00	Not applicable
IVR for NPDR without DME (LogMAR)	1 [16]	−0.13 (−0.24, −0.02)	0.02	Not applicable
IVR for NPDR without DME (Snellen)	1 [17]	0.15 (0.05, 0.25)	0.005	Not applicable
IVB for NPDR with DME (Snellen)	1 [14]	0.26 (0.10, 0.42)	0.002	Not applicable
IVR for NPDR with DME (Snellen)	2 [18, 20]	0.19 (0.10, 0.28)	0.00001	0	1.00
Total: (LogMAR)	4 [11, 12, 15, 16]	−0.07 (−0.11, −0.02)	0.006	21	0.29
Total: (Snellen)	4 [14, 17, 18, 20]	0.19 (0.12, 0.25)	0.00001	0	0.74

IVB = intravitreal bevacizumab; IVR = intravitreal ranibizumab; NPDR = nonproliferative diabetic retinopathy; BCVA = best-corrected visual acuity; DME = diabetic macular edema.